Clinical Trial Update: Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial completion evaluating a fusion protein cytokine therapy after Rituximab in patients with B-cell non-Hodgkin lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous B-cell Non-hodgkin Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Small Intestine Lymphoma
• Splenic Marginal Zone Lymphoma
• Waldenstrom Macroglobulinemia

Drugs mentioned

• Fusion Protein Cytokine Therapy
• Rituximab (rituximab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED